Managing severe Alzheimer's diseaseCanadian evidence-based guidelines support the use of a cholinesterase inhibitor or memantine, or both drugs for the management of patients with severe Alzheimer's disease. Aneurysm size, site are main predictors of ruptureLarger aneurysms and those in posterior circulation at highest risk, with age and comorbidities other key factors Enzymes offer promise as targets for treating progressive MS First Previous 53 54 55
